查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790419

美國肢端肥大症治療市場規模、佔有率和趨勢分析報告：按藥物類別、分銷管道和細分市場預測，2025-2033 年

U.S. Acromegaly Treatment Market Size, Share & Trends Analysis Report By Drug Class (Somatostatin Analogues, Growth Hormone Receptor Antagonists, Dopamine Agonists), By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國肢端肥大症治療市場摘要

美國肢端肥大症治療市場規模預計在 2024 年為 5.713 億美元，預計到 2033 年將達到 9.772 億美元，2025 年至 2033 年的複合年成長率為 6.2%。這是由於肢端肥大症的盛行率不斷上升且診斷更為早期，再加上 MRI 和 IGF-1 檢測等診斷工具的進步、認知的提高以及對疾病症狀的更好理解。

診斷技術的進步和個人化治療方法的採用有望促進早期發現和堅持治療。強大的醫療基礎設施、保險支援和多學科護理團隊預計將進一步推動市場擴張。

此外，新型生長抑制素類似物、生長激素受體拮抗劑以及個人化治療等治療方案的進展，提高了療效並減少了副作用。這些創新改善了患者的治療效果，擴大了治療範圍，刺激了市場需求，並鼓勵進一步的研發投入。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國肢端肥大症治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關市場展望
  • 產業價值鏈分析
  • 法律規範
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 產業挑戰
    • 行業機會
  • 產業分析工具
    • 波特五力分析
  • 打入市場策略

第4章消費行為分析

  • 人口統計分析
  • 消費者趨勢和偏好
  • 影響購買決策的因素
  • 消費者藥品類別採用
  • 觀察和建議

第5章美國肢端肥大症治療市場：藥物類別估計與趨勢分析

  • 美國肢端肥大症治療市場（按藥物類別）的關鍵要點
  • 2024 年及 2033 年藥品類別變化分析及市場佔有率
  • 依藥物類別，2021-2033 年
    • 生長抑制素類似物（SSA）
    • 生長激素受體拮抗劑（GHRAs）
    • 促效劑
    • 其他藥物類型（聯合治療、在研藥物）

第6章美國肢端肥大症治療市場：通路評估與趨勢分析

  • 美國肢端肥大症治療市場的通路：關鍵要點
  • 2024年及2033年通路變化分析及市場佔有率
  • 按分銷管道分類，2021-2033 年
    • 醫院藥房
    • 零售藥局
    • 其他

第7章美國肢端肥大症治療市場競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司熱圖/定位分析
  • 戰略地圖
  • 公司簡介
    • Novartis AG
    • Ipsen Pharma
    • Sun Pharmaceutical Industries Ltd
    • Chiasma, Inc.
    • Crinetics Pharmaceuticals
    • WOCKHARDT
    • Pfizer Inc.
    • Ionis Pharmaceuticals, Inc.
    • Teva Pharmaceuticals
Product Code: GVR-4-68040-675-1

U.S. Acromegaly Treatment Market Summary

The U.S. acromegaly treatment market size was estimated at USD 571.3 million in 2024 and is projected to reach USD 977.2 million by 2033, growing at a CAGR of 6.2% from 2025 to 2033. This is attributed to the rising prevalence of acromegaly and earlier diagnoses, coupled with advancements in diagnostic tools such as MRI and IGF-1 tests, improved awareness, and a better understanding of the disease's symptoms.

Technological advances in diagnostics and the adoption of personalized treatment regimens are expected to help early detection and adherence. Strong healthcare infrastructure, insurance support, and multidisciplinary care teams are further expected to support market expansion.

Moreover, advances in treatment options, including newer somatostatin analogs, growth hormone receptor antagonists, and personalized therapies, offer improved efficacy and fewer side effects. These innovations enhance patient outcomes and expand the treatment pool, fueling market demand and encouraging further investment in research and development.

U.S. Acromegaly Treatment Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. acromegaly treatment market report based on drug class, and distribution channel:

  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Somatostatin Analogues (SSAs)
  • Growth Hormone Receptor Antagonists (GHRAs)
  • Dopamine Agonists
  • Other Drug Types (Combination Therapies, Pipeline Drugs)
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources & Third-Party Perspectives
    • 1.3.4. Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Data Visualization
  • 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Acromegaly Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related Market Outlook
  • 3.2. Industry Value Chain Analysis
  • 3.3. Regulatory Framework
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
    • 3.4.2. Market Restraint Analysis
    • 3.4.3. Industry Challenges
    • 3.4.4. Industry Opportunities
  • 3.5. Industry Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
  • 3.6. Market Entry Strategies

Chapter 4. Consumer Behavior Analysis

  • 4.1. Demographic Analysis
  • 4.2. Consumer Trends and Preferences
  • 4.3. Factors Affecting Buying Decision
  • 4.4. Consumer Drug Class Adoption
  • 4.5. Observations & Recommendations

Chapter 5. U.S. Acromegaly Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. U.S. Acromegaly Treatment Market Drug Class: Key Takeaways
  • 5.2. Drug Class Movement Analysis & Market Share, 2024 & 2033
  • 5.3. U.S. Acromegaly Treatment Market Estimates & Forecast, By Drug Class, 2021 To 2033 (USD Million)
    • 5.3.1. Somatostatin Analogues (SSAs)
      • 5.3.1.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
    • 5.3.2. Growth Hormone Receptor Antagonists (GHRAs)
      • 5.3.2.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
    • 5.3.3. Dopamine Agonists
      • 5.3.3.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
    • 5.3.4. Other Drug Types (Combination Therapies, Pipeline Drugs)
      • 5.3.4.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)

Chapter 6. U.S. Acromegaly Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. U.S. Acromegaly Treatment Market Distribution Channel: Key Takeaways
  • 6.2. Distribution Channel Movement Analysis & Market Share, 2024 & 2033
  • 6.3. U.S. Acromegaly Treatment Market Estimates & Forecast, By Distribution Channel, 2021 to 2033 (USD Million)
    • 6.3.1. Hospital Pharmacies
      • 6.3.1.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)
    • 6.3.2. Retail Pharmacies
      • 6.3.2.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)
    • 6.3.3. Others
      • 6.3.3.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)

Chapter 7. U.S. Acromegaly Treatment Market - Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Heat Map/ Positioning Analysis
  • 7.3. Strategy Mapping
  • 7.4. Company Profiles
    • 7.4.1. Novartis AG
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Ipsen Pharma
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Sun Pharmaceutical Industries Ltd
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Chiasma, Inc.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Crinetics Pharmaceuticals
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. WOCKHARDT
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Pfizer Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Ionis Pharmaceuticals, Inc.
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Teva Pharmaceuticals
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives

List of Tables

  • Table 1. U.S. Acromegaly Treatment Market Estimates And Forecast, By Drug Class, 2021 - 2033 (USD Million)
  • Table 2. U.S. Acromegaly Treatment Market Estimates And Forecast, By Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. Acromegaly Treatment Market Segmentation
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Primary Research Approaches
  • Fig. 5 Primary Research Process
  • Fig. 6 Market Snapshot
  • Fig. 7 Drug Class Segment Snapshot
  • Fig. 8 Distribution Channel Segment Snapshot
  • Fig. 9 Competitive Landscape Snapshot
  • Fig. 10 U.S. Acromegaly Treatment Market Value, 2024 (USD Million)
  • Fig. 11 U.S. Acromegaly Treatment Market - Industry Value Chain Analysis
  • Fig. 12 U.S. Acromegaly Treatment Market Dynamics
  • Fig. 13 U.S. Acromegaly Treatment Market: Porter's Analysis
  • Fig. 14 U.S. Acromegaly Treatment Market, By Drug Class: Key Takeaways
  • Fig. 15 U.S. Acromegaly Treatment Market, By Drug Class: Market Share, 2024 & 2033
  • Fig. 16 Somatostatin Analogues (SSAs) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Growth Hormone Receptor Antagonists (GHRAs) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Dopamine Agonists Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Other Drug Types (Combination Therapies, Pipeline Drugs) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 U.S. Acromegaly Treatment Market, By Distribution Channel: Key Takeaways
  • Fig. 21 U.S. Acromegaly Treatment Market, By Distribution Channel: Market Share, 2024 & 2033
  • Fig. 22 Hospital Pharmacies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Retail Pharmacies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Key Company Categorization
  • Fig. 26 Strategic Framework